FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069241376> ?p ?o ?g. }

• W2069241376 abstract "Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FLBackground : There are currently no established markers to identify pts bearing wild-type EGFR who are likely to benefit from erlotinib (ERLO). The EGFR and Kras pathways, and epithelial to mesenchymal transition (EMT), have been associated with response/resistance to EGFR inhibitors. We developed gene signatures for these pathways and tested whether they were predictive of disease control (DC) and tumor mutations using gene expression profiles from pts in the BATTLE trial, and developed novel markers for ERLO benefit in wt EGFR pts.Methods : Gene expression profiles (Affymetrix HG1.0ST) from pretreatment core needle biopsies (CNBs) were obtained from 101 BATTLE pts. Pathways signatures were developed using independent datasets from resected NSCLC pts and cell lines. A robust EGFR mutation signature was derived by comparing genes differentially expressed in mutated and wt EGFR lung adenocarcinoma from 3 independent institutions, and validated in three independent sets, both in vivo and in vitro . A KRAS signature was similarly derived. An EMT signature was derived by identifying genes with a bimodal distribution and correlated with known EMT genes (E-cadherin, vimentin, N-cadherin, FN-1) using 54 NSCLC cell lines, and validated in an independent panel of HN cell lines and across different platforms. A novel 5-gene signature was derived using erlotinib-treated BATTLE patients with or without 8 week DC, the primary study endpoint.Results : The EGFR and Kras signatures predicted EGFR and Kras mutations, respectively, in BATTLE patients (AUC 0.72 by ROC analysis, p=0.03 for EGFR; AUC 0.67, p=0.0.01 for KRas signature). In pts with wt EGFR and Kras , the EMT and 5-gene, but not the EGFR or KRas signatures, were associated with improved DC in ERLO treated pts (EMT signature: 64% for epithelial vs 10% mesenchymal groups, p=0.02; 5-gene: 83% vs 0%, p=<.001) and progression-free survival (PFS). The EGFR, EMT and 5-gene signatures were also significantly associated with in vitro sensitivity to ERLO in NSCLC cell lines. LCN2/NGAL, part of the 5-gene signature, was found to be associated with the epithelial phenotype. Potential therapeutic targets associated with mesenchymal phenotype including Axl were identified by the EMT signature.Conclusions : Gene expression profiling from CNBs is a feasible approach for predicting response and identifying activated oncogenic pathways and potential therapeutic targets in refractory NSCLC pts. EGFR and Kras signatures predicted mutation status but, in wt EGFR patients, did not predict efficacy. EMT and a novel 5-gene signature including LCN2/NGAL were predictive of DC in pts with wt EGFR treated in BATTLE and merit further investigation as markers of benefit for EGFR inhibitors.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-88. doi:10.1158/1538-7445.AM2011-LB-88" @default.
• W2069241376 created "2016-06-24" @default.
• W2069241376 creator A5005076919 @default.
• W2069241376 creator A5008790176 @default.
• W2069241376 creator A5023062017 @default.
• W2069241376 creator A5023932021 @default.
• W2069241376 creator A5026079862 @default.
• W2069241376 creator A5028853785 @default.
• W2069241376 creator A5030693092 @default.
• W2069241376 creator A5034595514 @default.
• W2069241376 creator A5042586171 @default.
• W2069241376 creator A5048380048 @default.
• W2069241376 creator A5048865240 @default.
• W2069241376 creator A5056267838 @default.
• W2069241376 creator A5057281549 @default.
• W2069241376 creator A5062607977 @default.
• W2069241376 creator A5065373099 @default.
• W2069241376 creator A5066837969 @default.
• W2069241376 creator A5067386747 @default.
• W2069241376 creator A5067736041 @default.
• W2069241376 creator A5067755477 @default.
• W2069241376 creator A5069190968 @default.
• W2069241376 creator A5077579849 @default.
• W2069241376 creator A5080830668 @default.
• W2069241376 creator A5084597185 @default.
• W2069241376 creator A5085188591 @default.
• W2069241376 date "2011-04-15" @default.
• W2069241376 modified "2023-09-26" @default.
• W2069241376 title "Abstract LB-88: Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination)" @default.
• W2069241376 doi "https://doi.org/10.1158/1538-7445.am2011-lb-88" @default.
• W2069241376 hasPublicationYear "2011" @default.
• W2069241376 type Work @default.
• W2069241376 sameAs 2069241376 @default.
• W2069241376 citedByCount "1" @default.
• W2069241376 countsByYear W20692413762013 @default.
• W2069241376 crossrefType "proceedings-article" @default.
• W2069241376 hasAuthorship W2069241376A5005076919 @default.
• W2069241376 hasAuthorship W2069241376A5008790176 @default.
• W2069241376 hasAuthorship W2069241376A5023062017 @default.
• W2069241376 hasAuthorship W2069241376A5023932021 @default.
• W2069241376 hasAuthorship W2069241376A5026079862 @default.
• W2069241376 hasAuthorship W2069241376A5028853785 @default.
• W2069241376 hasAuthorship W2069241376A5030693092 @default.
• W2069241376 hasAuthorship W2069241376A5034595514 @default.
• W2069241376 hasAuthorship W2069241376A5042586171 @default.
• W2069241376 hasAuthorship W2069241376A5048380048 @default.
• W2069241376 hasAuthorship W2069241376A5048865240 @default.
• W2069241376 hasAuthorship W2069241376A5056267838 @default.
• W2069241376 hasAuthorship W2069241376A5057281549 @default.
• W2069241376 hasAuthorship W2069241376A5062607977 @default.
• W2069241376 hasAuthorship W2069241376A5065373099 @default.
• W2069241376 hasAuthorship W2069241376A5066837969 @default.
• W2069241376 hasAuthorship W2069241376A5067386747 @default.
• W2069241376 hasAuthorship W2069241376A5067736041 @default.
• W2069241376 hasAuthorship W2069241376A5067755477 @default.
• W2069241376 hasAuthorship W2069241376A5069190968 @default.
• W2069241376 hasAuthorship W2069241376A5077579849 @default.
• W2069241376 hasAuthorship W2069241376A5080830668 @default.
• W2069241376 hasAuthorship W2069241376A5084597185 @default.
• W2069241376 hasAuthorship W2069241376A5085188591 @default.
• W2069241376 hasConcept C104317684 @default.
• W2069241376 hasConcept C121608353 @default.
• W2069241376 hasConcept C126322002 @default.
• W2069241376 hasConcept C143998085 @default.
• W2069241376 hasConcept C150194340 @default.
• W2069241376 hasConcept C2776256026 @default.
• W2069241376 hasConcept C2777506169 @default.
• W2069241376 hasConcept C2778087573 @default.
• W2069241376 hasConcept C2779438470 @default.
• W2069241376 hasConcept C2779733811 @default.
• W2069241376 hasConcept C2781182431 @default.
• W2069241376 hasConcept C2781187634 @default.
• W2069241376 hasConcept C502942594 @default.
• W2069241376 hasConcept C526805850 @default.
• W2069241376 hasConcept C54355233 @default.
• W2069241376 hasConcept C71924100 @default.
• W2069241376 hasConcept C86803240 @default.
• W2069241376 hasConceptScore W2069241376C104317684 @default.
• W2069241376 hasConceptScore W2069241376C121608353 @default.
• W2069241376 hasConceptScore W2069241376C126322002 @default.
• W2069241376 hasConceptScore W2069241376C143998085 @default.
• W2069241376 hasConceptScore W2069241376C150194340 @default.
• W2069241376 hasConceptScore W2069241376C2776256026 @default.
• W2069241376 hasConceptScore W2069241376C2777506169 @default.
• W2069241376 hasConceptScore W2069241376C2778087573 @default.
• W2069241376 hasConceptScore W2069241376C2779438470 @default.
• W2069241376 hasConceptScore W2069241376C2779733811 @default.
• W2069241376 hasConceptScore W2069241376C2781182431 @default.
• W2069241376 hasConceptScore W2069241376C2781187634 @default.
• W2069241376 hasConceptScore W2069241376C502942594 @default.
• W2069241376 hasConceptScore W2069241376C526805850 @default.
• W2069241376 hasConceptScore W2069241376C54355233 @default.
• W2069241376 hasConceptScore W2069241376C71924100 @default.
• W2069241376 hasConceptScore W2069241376C86803240 @default.
• W2069241376 hasLocation W20692413761 @default.
• W2069241376 hasOpenAccess W2069241376 @default.
• W2069241376 hasPrimaryLocation W20692413761 @default.
• W2069241376 hasRelatedWork W1963905418 @default.
• W2069241376 hasRelatedWork W1964390945 @default.
• W2069241376 hasRelatedWork W1974997742 @default.

• next